Galapagos Soothed By Gilead's $725m Up Front For AbbVie Reject Filgotinib

Galapagos NV, which suffered a major shock in September when AbbVie decided not to exercise its option on their JAK1 inhibitor filgotinib, has secured $725m up front from Gilead Sciences Inc. for the promising rheumatoid arthritis treatment.